HIV prevention has expanded beyond daily oral medication to include long-acting injectable options. PrEP can substantially reduce the chance of acquiring HIV when used as prescribed. Current US options differ in dosing, administration, monitoring, and practical considerations, so understanding these differences can help people research which approaches may fit their circumstances.
HIV pre-exposure prophylaxis, commonly called PrEP, is medication for people who do not have HIV and may be exposed to HIV through sex or injection drug use. It is one part of a broader HIV prevention strategy.
PrEP is available in different forms. Depending on the medication and circumstances, prevention may involve oral tablets or an injectable medication administered by a healthcare professional.
The main differences between options involve:
PrEP does not prevent other sexually transmitted infections or pregnancy. Condoms can provide protection against certain other STIs and pregnancy.
What to remember: PrEP options are designed to reduce HIV acquisition risk, but they are not interchangeable in every situation. The appropriate option can depend on medical and practical factors.
Current US HIV PrEP options include oral medications and long-acting injectable medication. CDC guidance describes PrEP as an option for adults and adolescents without HIV who may be exposed to HIV through sex or injection drug use.
Oral PrEP involves taking medication by mouth according to the prescribed schedule. Some oral PrEP medications are tenofovir-based combinations.
Daily use is important because PrEP needs sufficient medication exposure to provide protection. CDC notes that the time required to reach maximum protection from daily PrEP pills varies according to the type of sexual exposure.
Oral medication may be considered convenient for someone who prefers taking a tablet rather than visiting a healthcare professional for injections. However, remembering doses consistently can be an important practical consideration.
Injectable PrEP provides another approach for people who prefer not to rely on frequent oral dosing.
Cabotegravir is an injectable PrEP option administered at regular intervals. More recently, injectable lenacapavir was approved in the US for PrEP, expanding the available HIV prevention options.
The differences between oral and injectable PrEP are not simply about convenience. Administration schedules, testing, clinical follow-up, side effects, and medication-specific requirements can all matter.
Lenacapavir is a long-acting HIV prevention medication that received FDA approval in June 2025 for PrEP to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk of HIV acquisition.
The PrEP formulation is marketed as Yeztugo. Its regimen begins with an injection and oral tablets, followed by a subcutaneous injection every six months. The FDA prescribing information specifies HIV testing before initiation and before subsequent injections.
This makes lenacapavir different from daily oral PrEP and from injectable PrEP that requires more frequent administration.
The CDC issued a clinical recommendation in September 2025 supporting twice-yearly injectable lenacapavir as an HIV PrEP option for people weighing at least 35 kg who would benefit from PrEP.
A six-month administration schedule means that a person does not need to remember a daily PrEP tablet. However, the longer interval also makes scheduled healthcare visits important.
Missing or delaying an injection can create a different type of adherence issue than forgetting an individual daily pill. Healthcare professionals can explain the recommended schedule and what to do if an appointment is missed.
There is no single factor that determines which PrEP option is appropriate. The practical differences can be considered across several areas.
| Consideration | Oral PrEP | Injectable PrEP |
|---|---|---|
| Administration | Taken by mouth | Administered by injection |
| Dosing frequency | Depends on prescribed regimen | Depends on medication |
| Healthcare visits | Follow-up and testing required | Injection visits required |
| Adherence consideration | Remembering prescribed doses | Keeping scheduled appointments |
| Side effects | Depend on medication | Depend on medication and injection |
| HIV testing | Required | Required |
| Drug interactions | Medication-specific | Medication-specific |
Injectable lenacapavir has a six-month continuation injection schedule, while other PrEP options have different dosing requirements. Therefore, comparing products solely by how often they are taken can overlook other clinically relevant differences.
When researching HIV PrEP options, consider:
These factors can make the practical experience of one prevention approach different from another.
Healthcare professionals may consider several factors when discussing HIV prevention options.
One consideration is how a person prefers to manage medication. Some people may prefer an oral medication they can take themselves, while others may prefer a long-acting injection administered during a healthcare visit.
Medical history can also matter. Kidney function, other medications, allergies, previous HIV testing results, and other health considerations may influence which PrEP options are appropriate.
Exposure patterns can also be relevant. CDC guidance recognizes that PrEP may be appropriate for people exposed to HIV through sex or injection drug use, although specific medications and evidence can differ according to the type of exposure.
For injectable lenacapavir, the current US indication is specifically for reducing the risk of sexually acquired HIV-1. CDC has also identified areas requiring additional research, including effectiveness among people who inject drugs.
Research point: The label, dosing schedule, and evidence for a medication matter more than treating all PrEP options as interchangeable.
HIV testing is an important part of PrEP care.
Before starting PrEP, a person must be tested for HIV to confirm that they do not already have HIV infection. Ongoing testing is also part of PrEP care.
For lenacapavir, the FDA prescribing information specifically warns about the risk of developing drug resistance if the medication is used in someone with undiagnosed HIV infection. The label requires HIV-1 testing before starting treatment and before each subsequent injection.
This is one reason PrEP should be managed with appropriate healthcare follow-up rather than treated as a medication that can simply be started and stopped without testing.
Follow-up care may include:
CDC recommends routine follow-up for people taking PrEP.
Cost can be an important part of researching HIV prevention, but the amount a person pays can vary substantially.
Factors may include:
CDC reports that most insurance plans and state Medicaid programs cover PrEP, while additional programs may help people who do not have insurance or Medicaid coverage.
Because coverage rules can change and differ by plan, researching PrEP insurance coverage and asking a healthcare provider or insurer about the specific medication can be more useful than relying on a general advertised price.
Access can also involve finding a healthcare professional who provides PrEP. CDC notes that PrEP can be prescribed by licensed healthcare professionals and provides resources for finding PrEP providers.
Before choosing or changing a PrEP approach, useful questions can include:
For lenacapavir specifically, it is useful to ask about the six-month injection schedule, required HIV testing, potential injection-site reactions, medication interactions, and what to do if an injection is delayed. The FDA label identifies injection-site reactions, headache, and nausea among the most common adverse reactions and includes specific HIV-testing requirements.
HIV PrEP has several prevention approaches, including oral medications and injectable options. The introduction of six-month injectable lenacapavir has expanded the choices available for sexually acquired HIV prevention in the US.
The important differences are not limited to dosing frequency. Administration method, HIV testing, monitoring, side effects, drug interactions, medical history, appointment requirements, cost, and insurance coverage can all affect how an option fits a person's circumstances.
For someone researching PrEP, the next useful step is usually to compare the options that are medically appropriate and discuss them with a qualified healthcare professional rather than assuming that one approach is universally preferable.